

### Alertas de Nuevas Actualizaciones

Una atención excepcional comienza con la **máxima confianza** en la información que se utiliza para **diagnosticar y tratar a los pacientes**. La mayoría de las veces, la mejor evidencia disponible proporciona esa tranquilidad. Pero la evidencia clínica no siempre ofrece una respuesta clara a una pregunta. La nueva estructura de contenidos de DynaMed ofrece a los clínicos la **combinación ideal de evidencia, complementada y aclarada por una orientación experta**.

Disponible en la pantalla inicial, el área de Alertas recientes muestra las actualizaciones más recientes del contenido de DynaMed. Además, al ver todas las Alertas Recientes en DynaMed, puede filtrar la lista de alertas por categoría para encontrar el contenido más recientemente actualizado que necesite.

#### Para ver las Alertas más recientes:

1. Puede alternar entre las alertas de los temas que sigue (requiere una cuenta de usuario personal) o todos los temas de DynaMed.
2. También puede filtrar ver únicamente las Alertas que pueden originar cambios en la práctica clínica.

The screenshot shows the DynaMed website interface. At the top, there is a navigation bar with 'Specialties', 'Recent Alerts', 'Drugs A-Z', 'Drug Interactions', 'Calculators', and 'About'. A search bar is present with a language dropdown set to 'Español' and a search button. The main content area is titled 'Recent Alerts' and includes a sub-header: 'Follow your specialty and individual topics to personalize alerts. Manage followed content.' Below this, there are two filter tabs: 'FOLLOWED' (highlighted with a yellow box) and 'ALL TOPICS'. Under the 'FOLLOWED' tab, there is a sub-filter 'Potentially Practice-Changing Only' indicated by an orange arrow. The list of alerts includes:
 

- Outbreak Alert** • Updated 31 Mar 2022: 17.5% of 68,911,849 confirmed cases reported to CDC with demographic data as of March 30, 2022 were in children < 18 years old (CDC 2022 Mar 30). View in COVID-19 and Pediatric Patients.
- Guideline Summary** • Updated 31 Mar 2022: Centers for Disease Control and Prevention (CDC) interim guidance for antigen testing for SARS-CoV-2 (CDC 2022 Mar 4). View in COVID-19 (Novel Coronavirus).
- Guideline Summary** • Updated 31 Mar 2022: National Institutes of Health (NIH) guideline on treatment of COVID-19, recommendations for laboratory diagnosis (NIH 2022 Mar 24). View in COVID-19 (Novel Coronavirus).
- Evidence** • Updated 31 Mar 2022.

 To the right of the alerts, there is a 'My Continuing Education' section for 'Benedita Arelas' showing 'Available CME/CPD/CE Credits: 25.0' and a 'Claim Credits' button. Below that is an 'Announcements' section with two items: 'DynaMed Named 2022 Best in KLAS' and 'NEW Thyroid Nodule Diagnosis Algorithm'. A 'Feedback' button is located at the bottom right of the page.

3. Pulse el botón de Alertas recientes para acceder a todas las alertas disponibles.

DynaMed BA CME 25.0 Buscar

Specialties **Recent Alerts** Drugs A-Z Drug Interactions Calculators About

### Recent Alerts

Filter by

**Evidence • Updated 31 Mar 2022**  
SARS-CoV-2 infection may be associated with increased risk of encephalomyelitis in adults not vaccinated against COVID-19 in the United Kingdom and Spain from September 2020 to June 2021 (BMJ 2022 Mar 16)  
View in Acute Disseminated Encephalomyelitis (ADEM)

**Evidence • Updated 31 Mar 2022**  
SARS-CoV-2 infection may be associated with increased risk of Guillain-Barre syndrome in adults not vaccinated against COVID-19 in the United Kingdom and Spain from September 2020 to June 2021 (BMJ 2022 Mar 16)  
View in Guillain-Barre Syndrome

**Evidence • Updated 31 Mar 2022**  
first dose of adenovirus vector COVID-19 vaccine (AstraZeneca) and mRNA COVID-19 vaccine (Pfizer-BioNTech) may each not be associated with increased risk of Guillain-Barre syndrome in adults in Spain and the United Kingdom (BMJ 2022 Mar 16)  
View in Guillain-Barre Syndrome

**Evidence • Updated 31 Mar 2022**  
COVID-19 vaccination may not be associated with increased risk of Bell palsy in adults in Spain and the United Kingdom (BMJ 2022 Mar 16)  
View in Bell Palsy

**Evidence • Updated 31 Mar 2022**

[Feedback](#)

4. Haga clic en el botón **Category** para filtrar las alertas mostradas; permite elegir 1 o varias categorías.

### Recent Alerts

Filter by **Category**


- Adult Primary Care
- Allergy
- Anesthesiology and Pain Management
- Cardiovascular Medicine
- Complementary and Alternative Medicine
- Critical Care Medicine
- Dermatology
- Drugs
- Ear, Nose and Throat (ENT) Medicine
- Emergency Medicine
- Endocrinology
- Family Medicine
- Gastroenterology
- Genetic Disorders
- Geriatric Medicine
- Hematology
- Hospital Medicine
- Immunology
- Infectious Diseases
- Nephrology
- Neurology
- Nutrition
- Obesity
- Obstetrics and Gynecology
- Occupational and Environmental Medicine
- Oncology
- Ophthalmology
- Oral and Maxillofacial Disorders
- Orthopedics and Sports Medicine
- Palliative Medicine
- Pathology and Laboratory Medicine
- Pediatrics
- Podiatry
- Prevention and Screening
- Psychiatry
- Pulmonary Medicine
- Quality Improvement
- Rheumatology
- Sleep Medicine
- Substance Use and Poisoning
- Surgery
- Urology

[Clear](#) [Apply](#)

5. El botón de categoría cambia de color para indicar que se ha filtrado la lista de alertas.

### Recent Alerts

---

Filter by **Category** 

---

**Drug/Device Alert** • Updated 30 Mar 2022

upadacitinib (Rinvoq) receives expanded FDA approval for treatment of moderate-to-severely active ulcerative colitis in adults with inadequate response or intolerance to  $\geq 1$  TNF inhibitor (FDA DailyMed 2022 Mar 16)

[View in Ulcerative Colitis in Adults](#)

**Drug/Device Alert** • Updated 30 Mar 2022

lutetium Lu 177 vipivotide tetraxetan (Pluvicto) FDA approved for treatment of PSMA-positive metastatic castration-resistant prostate cancer in adults who have been treated with androgen receptor pathway inhibition therapy and taxane-based chemotherapy (FDA Press Release 2022 Mar 23)

[View in Management of Castration-resistant Prostate Cancer](#)

**Drug/Device Alert** • Updated 30 Mar 2022

donepezil transdermal system (Adlarity) FDA approved for treatment of mild, moderate, and severe Alzheimer dementia (FDA DailyMed 2022 Mar 11)

[View in Alzheimer Dementia](#)

**Drug/Device Alert** • Updated 30 Mar 2022

olaparib (Lynparza) receives expanded FDA approval for adjuvant treatment of high-risk, early breast cancer in adults with deleterious or suspected deleterious germline BRCA-mutated and HER2 negative disease who have been treated with neoadjuvant or adjuvant chemotherapy (FDA Press Release 2022 Mar 11)

[View in Chemotherapy for Early and Locally Advanced Breast Cancer](#)

**Evidence** • Updated 29 Mar 2022

ulcerative colitis and longer disease duration prior to anti-TNF treatment each associated with increased drug-induced lupus in adults with inflammatory bowel disease treated with anti-TNF agent in South Korea (Therap Adv Gastroenterol 2021)

[View in Drug-induced Lupus](#)